

Patrycja Nowak-Sliwinska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6366916/publications.pdf>

Version: 2024-02-01

90
papers

4,994
citations

101543

36
h-index

95266

68
g-index

96
all docs

96
docs citations

96
times ranked

7738
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus guidelines for the use and interpretation of angiogenesis assays. <i>Angiogenesis</i> , 2018, 21, 425-532.	7.2	429
2	The chicken chorioallantoic membrane model in biology, medicine and bioengineering. <i>Angiogenesis</i> , 2014, 17, 779-804.	7.2	334
3	In Vitro and In Vivo Photocytotoxicity of Boron Dipyrromethene Derivatives for Photodynamic Therapy. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 2865-2874.	6.4	311
4	Organometallic Ruthenium(II) Arene Compounds with Antiangiogenic Activity. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 3895-3902.	6.4	229
5	<i>In vivo</i> anti-tumor activity of the organometallic ruthenium(II)-arene complex [Ru(η^6 -p-cymene)Cl ₂ (pta)] (RAPTA-C) in human ovarian and colorectal carcinomas. <i>Chemical Science</i> , 2014, 5, 4742-4748.	7.4	224
6	The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy. <i>Pharmacological Reviews</i> , 2015, 67, 441-461.	16.0	190
7	Anti-angiogenic agents "overcoming tumour endothelial cell energy and improving immunotherapy outcomes. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 527-540.	27.6	162
8	Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients. <i>Clinical Cancer Research</i> , 2012, 18, 3961-3971.	7.0	138
9	Indocyanine green as a prospective sensitizer for photodynamic therapy of melanomas.. <i>Acta Biochimica Polonica</i> , 2002, 49, 387-391.	0.5	133
10	Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 434-454.	7.4	131
11	COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects. <i>Angiogenesis</i> , 2021, 24, 755-788.	7.2	114
12	The role of glycolysis and mitochondrial respiration in the formation and functioning of endothelial tip cells during angiogenesis. <i>Scientific Reports</i> , 2019, 9, 12608.	3.3	113
13	Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer. <i>Angiogenesis</i> , 2015, 18, 233-244.	7.2	108
14	Modulating the Anticancer Activity of Ruthenium(II)-Arene Complexes. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 3356-3365.	6.4	99
15	Combination of ruthenium(II)-arene complex [Ru(η^6 -p-cymene)Cl ₂ (pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity. <i>Scientific Reports</i> , 2017, 7, 43005.	3.3	97
16	Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma. <i>Scientific Reports</i> , 2019, 9, 7103.	3.3	95
17	Role of the tumor stroma in resistance to anti-angiogenic therapy. <i>Drug Resistance Updates</i> , 2016, 25, 26-37.	14.4	88
18	Optimization of drug combinations using Feedback System Control. <i>Nature Protocols</i> , 2016, 11, 302-315.	12.0	86

#	ARTICLE	IF	CITATIONS
19	Photodynamic therapy for polypoidal choroidal vasculopathy. <i>Progress in Retinal and Eye Research</i> , 2013, 37, 182-199.	15.5	82
20	Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane. <i>Angiogenesis</i> , 2010, 13, 281-292.	7.2	77
21	A streamlined search technology for identification of synergistic drug combinations. <i>Scientific Reports</i> , 2015, 5, 14508.	3.3	72
22	Targeting PDGF-mediated recruitment of pericytes blocks vascular mimicry and tumor growth. <i>Journal of Pathology</i> , 2018, 246, 447-458.	4.5	67
23	Processing of fluorescence angiograms for the quantification of vascular effects induced by anti-angiogenic agents in the CAM model. <i>Microvascular Research</i> , 2010, 79, 21-28.	2.5	60
24	Discovery of a Highly Tumor-Selective Organometallic Ruthenium(II)-Arene Complex. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 3546-3558.	6.4	60
25	Thermoresponsive organometallic arene ruthenium complexes for tumour targeting. <i>Chemical Science</i> , 2014, 5, 1097.	7.4	59
26	Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy. <i>Scientific Reports</i> , 2015, 5, 8990.	3.3	58
27	Recent Considerations in the Application of RAPTAs for Cancer Treatment and Perspectives for Its Combination with Immunotherapies. <i>Advanced Therapeutics</i> , 2019, 2, 1900042.	3.2	57
28	miRNAs: micro-managers of anticancer combination therapies. <i>Angiogenesis</i> , 2017, 20, 269-285.	7.2	55
29	Verteporfin, photofrin II, and merocyanine 540 as PDT photosensitizers against melanoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2006, 349, 549-555.	2.1	54
30	Functional consequences of prolactin signalling in endothelial cells: a potential link with angiogenesis in pathophysiology?. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 2035-2048.	3.6	52
31	Synthesis and characterization of a new class of anti-angiogenic agents based on ruthenium clusters. <i>Scientific Reports</i> , 2013, 3, 1485.	3.3	47
32	Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 480-491.	3.6	46
33	Angiostatic kinase inhibitors to sustain photodynamic angioclusion. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 1553-1562.	3.6	43
34	Real-time, <i>in vivo</i> measurement of tissular pO ₂ through the delayed fluorescence of endogenous protoporphyrin IX during photodynamic therapy. <i>Journal of Biomedical Optics</i> , 2012, 17, 115007.	2.6	41
35	Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug. <i>ChemMedChem</i> , 2018, 13, 1210-1217.	3.2	40
36	Angiogenesis inhibition for the improvement of photodynamic therapy: The revival of a promising idea. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1826, 53-70.	7.4	37

#	ARTICLE	IF	CITATIONS
37	Current Trends in Multidrug Optimization: An Alley of Future Successful Treatment of Complex Disorders. <i>SLAS Technology</i> , 2017, 22, 254-275.	1.9	33
38	Interfering with UDP-GlcNAc Metabolism and Heparan Sulfate Expression Using a Sugar Analogue Reduces Angiogenesis. <i>ACS Chemical Biology</i> , 2013, 8, 2331-2338.	3.4	32
39	Insulin-like growth factor axis targeting in cancer and tumour angiogenesis – the missing link. <i>Biological Reviews</i> , 2017, 92, 1755-1768.	10.4	32
40	IGF2 and IGF1R identified as novel tip cell genes in primary microvascular endothelial cell monolayers. <i>Angiogenesis</i> , 2018, 21, 823-836.	7.2	30
41	Towards Light-Activated Ruthenium-Arene (RAPTA-type) Prodrug Candidates. <i>ChemBioChem</i> , 2019, 20, 2876-2882.	2.6	30
42	Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment. <i>Molecules</i> , 2020, 25, 2614.	3.8	30
43	The Neovessel Occlusion Efficacy of 15 ¹ -Hydroxypurpurin-7-Lactone Dimethyl Ester Induced with Photodynamic Therapy. <i>Photochemistry and Photobiology</i> , 2010, 86, 397-402.	2.5	29
44	Discovery of a low order drug-cell response surface for applications in personalized medicine. <i>Physical Biology</i> , 2014, 11, 065003.	1.8	29
45	Optimization and regeneration kinetics of lymphatic-specific photodynamic therapy in the mouse dermis. <i>Angiogenesis</i> , 2014, 17, 347-357.	7.2	29
46	Antiangiogenic and Anticancer Properties of Bifunctional Ruthenium(II)-p-Cymene Complexes: Influence of Pendant Perfluorous Chains. <i>Molecular Pharmaceutics</i> , 2015, 12, 3089-3096.	4.6	27
47	Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy. <i>Nature Communications</i> , 2022, 13, .	12.8	27
48	Chlorambucil conjugates of dinuclear p-cymene ruthenium trithiolato complexes: synthesis, characterization and cytotoxicity study in vitro and in vivo. <i>Journal of Biological Inorganic Chemistry</i> , 2016, 21, 443-452.	2.6	26
49	In vivo evaluation of small-molecule thermoresponsive anticancer drugs potentiated by hyperthermia. <i>Chemical Science</i> , 2015, 6, 2795-2801.	7.4	25
50	Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment. <i>Angiogenesis</i> , 2017, 20, 245-267.	7.2	25
51	Beyond mouse cancer models: Three-dimensional human-relevant in vitro and non-mammalian in vivo models for photodynamic therapy. <i>Mutation Research - Reviews in Mutation Research</i> , 2017, 773, 242-262.	5.5	25
52	Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering. <i>Cancers</i> , 2019, 11, 1612.	3.7	25
53	Patient-Derived In Vitro Models for Drug Discovery in Colorectal Carcinoma. <i>Cancers</i> , 2020, 12, 1423.	3.7	25
54	Anticancer Organometallic Osmium(II)-p-Cymene Complexes. <i>ChemMedChem</i> , 2015, 10, 1539-1547.	3.2	23

#	ARTICLE	IF	CITATIONS
55	<i>In vivo</i> measurement of tissue oxygenation by time-resolved luminescence spectroscopy: advantageous properties of dichlorotris(1, 10-phenanthroline)-ruthenium(II) hydrate. <i>Journal of Biomedical Optics</i> , 2014, 19, 077004.	2.6	22
56	A key role for galectin-1 in sprouting angiogenesis revealed by novel rationally designed antibodies. <i>International Journal of Cancer</i> , 2016, 139, 824-835.	5.1	21
57	An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature. <i>Vaccine</i> , 2018, 36, 3054-3060.	3.8	21
58	Oncofetal insulin receptor isoform A marks the tumour endothelium; an underestimated pathway during tumour angiogenesis and angiostatic treatment. <i>British Journal of Cancer</i> , 2019, 120, 218-228.	6.4	20
59	Optimized low-dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment. <i>Molecular Oncology</i> , 2020, 14, 2894-2919.	4.6	20
60	The emerging quest for the optimal angiostatic combination therapy. <i>Biochemical Society Transactions</i> , 2014, 42, 1608-1615.	3.4	19
61	Optimized Combination of HDACi and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance. <i>Cancers</i> , 2020, 12, 3172.	3.7	17
62	Improved Angiostatic Activity of Dasatinib by Modulation with Hydrophobic Chains. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 313-317.	2.8	16
63	A genomic screen for angiosuppressor genes in the tumor endothelium identifies a multifaceted angiostatic role for bromodomain containing 7 (BRD7). <i>Angiogenesis</i> , 2017, 20, 641-654.	7.2	16
64	Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma. <i>British Journal of Cancer</i> , 2020, 123, 556-567.	6.4	16
65	Angiogenesis inhibition by the maleimide-based small molecule GNX-686. <i>Microvascular Research</i> , 2012, 83, 105-110.	2.5	15
66	Thermoresponsive fluorinated small-molecule drugs: a new concept for efficient localized chemotherapy. <i>MedChemComm</i> , 2015, 6, 2054-2062.	3.4	15
67	Highly water soluble trithiolato-bridged dinuclear arene ruthenium complexes. <i>Inorganica Chimica Acta</i> , 2014, 423, 524-529.	2.4	14
68	Colorectal Cancer Growth Retardation through Induction of Apoptosis, Using an Optimized Synergistic Cocktail of Axitinib, Erlotinib, and Dasatinib. <i>Cancers</i> , 2019, 11, 1878.	3.7	13
69	Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression. <i>British Journal of Cancer</i> , 2019, 121, 139-149.	6.4	12
70	Characterization of Renal Cell Carcinoma Heterotypic 3D Co-Cultures with Immune Cell Subsets. <i>Cancers</i> , 2021, 13, 2551.	3.7	12
71	Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6467.	4.1	12
72	Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3978.	3.7	12

#	ARTICLE	IF	CITATIONS
73	Angiostasis-induced vascular normalization can improve photodynamic therapy. Cellular and Molecular Life Sciences, 2010, 67, 1559-1560.	5.4	11
74	Increasing the selectivity of biologically active tetranuclear arene ruthenium assemblies. Journal of Organometallic Chemistry, 2015, 796, 59-64.	1.8	11
75	Spectral Characteristic and Preliminary Anticancer Activity <i>in vitro</i> of Selected Rhodanine- β -carboxylic Acids Derivatives. Journal of Heterocyclic Chemistry, 2017, 54, 2889-2897.	2.6	11
76	Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment. Cancers, 2020, 12, 2697.	3.7	11
77	Current Trends in Multidrug Optimization. Journal of the Association for Laboratory Automation, 2017, , 221106821668233.	2.8	10
78	Study of the pO ₂ -Sensitivity of the Dendrimeric and Free Forms of Pd-meso-tetra(4-carboxyphenyl)porphyrin, Incorporated or not in Chitosan-Based Nanoparticles. Chimia, 2011, 65, 691.	0.6	9
79	Apoptosis on the move. Apoptosis: an International Journal on Programmed Cell Death, 2018, 23, 251-254.	4.9	7
80	Apoptosis turns 21. Apoptosis: an International Journal on Programmed Cell Death, 2017, 22, 1485-1486.	4.9	6
81	Anti-Angiogenic Treatment for Exudative Age-Related Macular Degeneration: New Strategies are Underway. Current Angiogenesis, 2012, 1, 318-334.	0.1	5
82	Angiogenesis inhibitors in combinatorial approaches. Angiogenesis, 2017, 20, 183-184.	7.2	5
83	A quarter century of Apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2021, 26, 233-234.	4.9	4
84	Vascular effects induced by anti-VEGF agents in the CAM model: effect of the DMSO. , 2009, , .		3
85	Anti-angiogenic properties of chlorambucil derivatives with fluorous and hydrocarbon appendages. MedChemComm, 2016, 7, 1596-1603.	3.4	3
86	Cell death rocks. Apoptosis: an International Journal on Programmed Cell Death, 2019, 24, 205-207.	4.9	3
87	Programmed death, cells on the last train to glory. Apoptosis: an International Journal on Programmed Cell Death, 2020, 25, 151-153.	4.9	3
88	Forcing dividing cancer cells to die; low-dose drug combinations to prevent spindle pole clustering. Apoptosis: an International Journal on Programmed Cell Death, 2021, 26, 248-252.	4.9	3
89	Optimization for multidrug combinations: Challenges and perspectives in complex disorders. Pharmacological Research, 2020, 154, 104165.	7.1	2
90	Effect of preoperative antiangiogenic treatment and subsequent discontinuation on angiogenesis in the primary tumor in patients with RCC.. Journal of Clinical Oncology, 2012, 30, 350-350.	1.6	2